ReviewInternational journal of molecular sciences2013
Sarcosine as a potential prostate cancer biomarker--a review.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 127 citations in OpenAlex.
- Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population.Medical oncology (Northwood, London, England) · 2026Review
- Design and optimization of a Cu-MOF@graphene oxide nanozyme for point-of-care colorimetric determination of sarcosine and HRSC advances · 2026Article
- High Plasma Sarcosine Levels Are Associated with Decreased Risks of Adverse Outcomes After Ischemic Stroke: A Multicenter Prospective Study.Translational stroke research · 2025Article
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- MXene and prostate cancer: is there promising news?Nanomedicine (London, England) · 2025Review
- A pilot study on hemodynamically stable isolated chest trauma patients reveals dysregulation of oxidative metabolism.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Malignant Transformed and Non-Transformed Oral Leukoplakias Are Metabolically Different.International journal of molecular sciences · 2025Article
- Prostate cancer risk biomarkers from large cohort and prospective metabolomics studies: A systematic review.Translational oncology · 2025Review
- ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production.International journal of molecular sciences · 2023Article
- Plasma metabolomics of oral squamous cell carcinomas based on NMR and MS approaches provides biomarker identification and survival prediction.Scientific reports · 2023Article
- Amperometric Miniaturised Portable Enzymatic Nanobiosensor for the Ultrasensitive Analysis of a Prostate Cancer Biomarker.Journal of functional biomaterials · 2023Article
- Silica Nanospheres Coated Silver Islands as an Effective Opto-Plasmonic SERS Active Platform for Rapid and Sensitive Detection of Prostate Cancer Biomarkers.Molecules (Basel, Switzerland) · 2022Article
- Role of Serum Creatinine Levels in Prognostic Risk Stratification of Prostate Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Towards Multiplexed and Multimodal Biosensor Platforms in Real-Time Monitoring of Metabolic Disorders.Sensors (Basel, Switzerland) · 2022Review
- Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.Scientific reports · 2022Article
- A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.Metabolites · 2021Article
- Aromatic amino acids play a harmonizing role in prostate cancer: A metabolomics-based cross-sectional study.International journal of reproductive biomedicine · 2021Article
- Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts.Cancers · 2021Article
- Urinary Biomarkers in Tumors: An Overview.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Metabolism of prostate cancer by magnetic resonance spectroscopy (MRS).Biophysical reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated. According to that fact, there is great interest in the finding of new markers including amino acids, proteins or nucleic acids. Prostate specific antigen (PSA) is commonly used and is the most important biomarker of CaP. This marker can only be detected in blood and its sensitivity is approximately 80%. Moreover, early stages cannot be diagnosed using this protein. Currently, there does not exist a test for diagnosis of early stages of prostate cancer. This fact motivates us to find markers sensitive to the early stages of CaP, which are easily detected in body fluids including urine. A potential is therefore attributed to the non-protein amino acid sarcosine, which is generated by glycine-N-methyltransferase in its biochemical cycle. In this review, we summarize analytical methods for quantification of sarcosine as a CaP marker. Moreover, pathways of the connection of synthesis of sarcosine and CaP development are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.